Bristol-Myers Squibb will open a new facility in Florida to support operations, creating 575 jobs in the process.
A recent report put Bristol-Myers Squibb at the back of the line in terms of Big Pharma companies that are hiring right now. But that is of little interest to Florida, which just nabbed the company for a new development near Tampa that it promises to fill with more than 575 jobs.
Street talk about Big Pharma bidders for Onyx Pharmaceuticals puts Pfizer and Bristol-Myers Squibb in the hunt, with biotech giant Amgen still leading the charge.
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
The FDA will consider Eliquis for a new indication, one which Pfizer and partner Bristol-Myers Squibb hope can help the blood thinner hit the sales potential analysts predicted for the drug before it was approved.
The allegations could raise more questions about the integrity of drug research in China.
Nearly 7 months since the FDA approved the blockbuster candidate Eliquis, media reports have shed light on data errors and a case of alleged fraud from clinical trial sites in China. The revelations in reports from Elsevier and Bloomberg could further harm the image of China as a hotspot for clinical development.
The world's biggest drugmakers are hiring--even in the U.S. and Europe. As Genetic Engineering & Biotechnology News numbers show, the three most active recruiters have more than 5,000 positions to fill between them.
Pfizer and Bristol-Myers Squibb announced today that their anticoagulant drug Eliquis matched standard treatment for potentially life-threatening blood clots, efficacy-wise. And it beat warfarin on the safety side, with a 69% reduction in the risk of major bleeding.
A labeling addition approved by the FDA Thursday for Bristol-Myers Squibb's leukemia drug Sprycel can only help to make up for the $4.5 billion in lost revenues since the blood thinner Plavix went off patent last year.